Literature DB >> 16456238

Angiotensin preconditioning of the heart: evidence for redox signaling.

Samarjit Das1, Richard M Engelman, Nilanjana Maulik, Dipak K Das.   

Abstract

Angiotensin II (Ang II) has been found to exert preconditioning-like effect on mammalian hearts. Diverse mechanisms are known to exist to explain the cardioprotective abilities of Ang II preconditioning. The present study hypothesized, based on the recent report that Ang II generates reactive oxygen species (ROS) through NADPH oxidase, that Ang II preconditioning occurs through redox cycling. To test this hypothesis, a group of rat hearts was treated with Ang II in the absence or presence of an NADPH oxidase inhibitor, apocynin; or a cell-permeable ROS scavenger, N-acetyl cysteine (NAC). Ang II pretreatment improved postischemic ventricular recovery; reduced myocardial infarction; and decreased the number of cardiomyocyte apoptosis, indicating its ability to precondition the heart against ischemic injury. Both apocynin and NAC almost abolished the preconditioning ability of Ang II. Ang II resulted in increase in ROS activity in the heart, which was reduced by either NAC or apocynin. Ang II also increased both the NADPH oxidase subunits gp91 phox and p22phox mRNA expression, which was abolished with apocynin and NAC. Our results thus demonstrate that the Ang II preconditioning was associated with enhanced ROS activities and increased NADPH oxidase subunits p22phox and gp91phox expression. Both NAC and apocynin reduced ROS activities simultaneously abolishing preconditioning ability of Ang II, suggesting that Ang II preconditioning occurs through redox cycling. That both NAC and apocynin reduced ROS activities and abolished Ang II-mediated increase in p22phox and gp91phox activity further suggest that such redox cycling occurs via both NADPH oxidase-dependent and -independent pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456238     DOI: 10.1385/CBB:44:1:103

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  8 in total

1.  NADPH oxidase modulates myocardial Akt, ERK1/2 activation, and angiogenesis after hypoxia-reoxygenation.

Authors:  Jian-Xiong Chen; Heng Zeng; Qin-Hui Tuo; Heidi Yu; Barbara Meyrick; Judy L Aschner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-01-12       Impact factor: 4.733

2.  Angiotensin II-preconditioning is associated with increased PKCε/PKCδ ratio and prosurvival kinases in mitochondria.

Authors:  Rebeca E Nuñez; Sabzali Javadov; Nelson Escobales
Journal:  Clin Exp Pharmacol Physiol       Date:  2017-09-20       Impact factor: 2.557

Review 3.  Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation.

Authors:  Husnain Kh Haider; Muhammad Ashraf
Journal:  J Mol Cell Cardiol       Date:  2008-05-10       Impact factor: 5.000

4.  Angiotensin II and ischemic preconditioning synergize to improve mitochondrial function while showing additive effects on ventricular postischemic recovery.

Authors:  Rebeca E Nuñez; Miriam Castro; Sabzali Javadov; Nelson Escobales
Journal:  J Cardiovasc Pharmacol       Date:  2014-08       Impact factor: 3.105

5.  AngiotensinII preconditioning promotes angiogenesis in vitro via ERKs phosphorylation.

Authors:  Aili Guan; Yunzeng Zou; Hui Gong; Yuhong Niu; Yong Ye; Jianguo Jia; Bingyu Li; Guoping Zhang; Sanli Qian; Junbo Ge
Journal:  J Biomed Biotechnol       Date:  2012-02-28

6.  Oxygen Sensing, Cardiac Ischemia, HIF-1α and Some Emerging Concepts.

Authors:  Shyamal K Goswami; Dipak K Das
Journal:  Curr Cardiol Rev       Date:  2010-11

7.  Caveolin and MAP kinase interaction in angiotensin II preconditioning of the myocardium.

Authors:  Manika Das; Samarjit Das; Dipak K Das
Journal:  J Cell Mol Med       Date:  2007 Jul-Aug       Impact factor: 5.310

8.  Intermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: role of BK2 receptors.

Authors:  Luca Sgarra; Valentina Leo; Francesco Addabbo; Dominga Iacobazzi; Maria Rosaria Carratù; Monica Montagnani; Maria Assunta Potenza
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.